Page 50 - ரிக் பவுமர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pfizer-BioNTech study shows COVID-19 vaccine continues to be more than 90% effective for at least 6 months

Pfizer COVID-19 vaccine is 90% effective for at least 6 months and protects against South Africa variant, study shows Karen Weintraub, USA TODAY What to watch next Replay Video UP NEXT Six months after getting a second dose of the Pfizer-BioNTech vaccine as part of a 46,000-person clinical trial, volunteers remained more than 90% protected against symptomatic COVID-19 and even better protected against severe disease, a new company study found. © Rick Bowmer, AP Allison Oler, 17, receives her Pfizer vaccination, Wednesday, March 24, 2021, in Sandy, Utah. All adults in Utah aged 16 and older became eligible to receive COVID-19 vaccinations Wednesday. (AP Photo/Rick Bowmer) Out of 927 trial participants who fell ill with COVID-19 more than a week after their second dose, only 77 had received the active vaccine, compared with 850 who got a placebo.

United statesSouth africaAllison olerLuciana borioAlbert bourlaEdith arangoitiaRick bowmerJacob sherkowBiontech covidUgur sahinCenters for diseaseUniversity of illinois college lawDrug administrationOxford universityEmergency use authorizationsBiologics license application

Pfizer COVID-19 vaccine is 90% effective for at least 6 months and protects against South Africa variant, study shows

Pfizer COVID-19 vaccine is 90% effective for at least 6 months and protects against South Africa variant, study shows Karen Weintraub, USA TODAY Replay Video Six months after getting a second dose of the Pfizer-BioNTech vaccine as part of a 46,000-person clinical trial, volunteers remained more than 90% protected against symptomatic COVID-19 and even better protected against severe disease, a new company study found. © Rick Bowmer, AP Allison Oler, 17, receives her Pfizer vaccination, Wednesday, March 24, 2021, in Sandy, Utah. All adults in Utah aged 16 and older became eligible to receive COVID-19 vaccinations Wednesday. (AP Photo/Rick Bowmer) Out of 927 trial participants who fell ill with COVID-19 more than a week after their second dose, only 77 had received the active vaccine, compared with 850 who got a placebo.

United statesSouth africaAllison olerLuciana borioAlbert bourlaEdith arangoitiaRick bowmerJacob sherkowBiontech covidUgur sahinCenters for diseaseUniversity of illinois college lawDrug administrationOxford universityBiologics license applicationIllinois college

Pfizer COVID-19 vaccine is 90% effective for at least 6 months and protects against South Africa variant, study shows

Pfizer COVID-19 vaccine is 90% effective for at least 6 months and protects against South Africa variant, study shows
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.

United statesSouth africaAllison olerLuciana borioAlbert bourlaEdith arangoitiaRick bowmerJacob sherkowBiontech covidUgur sahinCenters for diseaseDrug administrationOxford universityUniversity of illinois at urbana champaignCollege of lawBiologics license application

Pfizer COVID-19 vaccine is 90% effective for at least 6 months and protects against South Africa variant, study shows

United statesSouth africaAllison olerLuciana borioAlbert bourlaEdith arangoitiaRick bowmerJacob sherkowBiontech covidUgur sahinCenters for diseaseUniversity of illinois college lawDrug administrationOxford universityEmergency use authorizationsBiologics license application

Pfizer and Moderna vaccines 90% effective in preventing COVID, says US

Pfizer and Moderna vaccines 90% effective in preventing COVID, says US
timesofisrael.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from timesofisrael.com Daily Mail and Mail on Sunday newspapers.

District of columbiaUnited statesUnited kingdomWhite houseSalt lake cityCapitol hillSpanish forkMark thompsonRochelle walenskyLogan garnicaSusan walshDavid holtgraveCenters for diseaseUniversity at albany school of public healthDisease controlPublic health